Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Panagiotis J Vlachostergios

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
Current Urology|January 24, 2022
Combined DNA repair defects in testicular metastasis from prostate cancer sensitize to immune checkpoint blockadePanagiotis J Vlachostergios
Translational Cancer Research|April 14, 2025
Circulating tumor cell-based PSMA and PSA expression as a predictive and prognostic tool in prostate cancerPanagiotis J Vlachostergios
Exploration of Targeted Anti-Tumor Therapy|December 1, 2025
Cancer vaccines: advances, hurdles, and future directionsPanagiotis J Vlachostergios
Precision Clinical Medicine|June 13, 2022
The interplay of cell cycle and DNA repair gene alterations in upper tract urothelial carcinoma: predictive and prognostic implicationsPanagiotis J Vlachostergios
Expert Review of Anticancer Therapy|July 4, 2025
PSMA PET or conventional imaging in metastatic hormone-sensitive prostate cancer?Panagiotis J Vlachostergios
Journal of Kidney Cancer and VHL|September 28, 2020
Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic EvaluationPanagiotis J Vlachostergios
American Journal of Translational Research|December 27, 2021
Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitorsPanagiotis J Vlachostergios
Translational Oncology|April 15, 2021
Loss of tumor suppressive properties of lipid metabolism enzyme CPT2 in ovarian carcinoma: Comment on "CPT2 down-regulation promotes tumor growth and metastasis through inducing ROS/NFκB pathway in ovarian cancer" by Zhang et alPanagiotis J Vlachostergios
Molecular Cancer Therapeutics|May 20, 2014
Efficacy of zibotentan in colorectal cancer--letterPanagiotis J Vlachostergios
Urologic Oncology|July 30, 2025
Leveraging DNA repair deficiency to personalize radiopharmaceutical therapy in prostate cancerPanagiotis J Vlachostergios
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
Current Urology|January 24, 2022
Combined DNA repair defects in testicular metastasis from prostate cancer sensitize to immune checkpoint blockadePanagiotis J Vlachostergios
Translational Cancer Research|April 14, 2025
Circulating tumor cell-based PSMA and PSA expression as a predictive and prognostic tool in prostate cancerPanagiotis J Vlachostergios
Exploration of Targeted Anti-Tumor Therapy|December 1, 2025
Cancer vaccines: advances, hurdles, and future directionsPanagiotis J Vlachostergios
Precision Clinical Medicine|June 13, 2022
The interplay of cell cycle and DNA repair gene alterations in upper tract urothelial carcinoma: predictive and prognostic implicationsPanagiotis J Vlachostergios
Expert Review of Anticancer Therapy|July 4, 2025
PSMA PET or conventional imaging in metastatic hormone-sensitive prostate cancer?Panagiotis J Vlachostergios
Journal of Kidney Cancer and VHL|September 28, 2020
Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic EvaluationPanagiotis J Vlachostergios
American Journal of Translational Research|December 27, 2021
Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitorsPanagiotis J Vlachostergios
Translational Oncology|April 15, 2021
Loss of tumor suppressive properties of lipid metabolism enzyme CPT2 in ovarian carcinoma: Comment on "CPT2 down-regulation promotes tumor growth and metastasis through inducing ROS/NFκB pathway in ovarian cancer" by Zhang et alPanagiotis J Vlachostergios
Molecular Cancer Therapeutics|May 20, 2014
Efficacy of zibotentan in colorectal cancer--letterPanagiotis J Vlachostergios
Urologic Oncology|July 30, 2025
Leveraging DNA repair deficiency to personalize radiopharmaceutical therapy in prostate cancerPanagiotis J Vlachostergios
Pageof 12